If you have been recently diagnosed with a brain tumor or looking for a second opinion, you and your family may be facing a lot of difficult questions. It's vital to learn your options and take action right away. City of Hope is a leader in the research, diagnosis and treatment of brain tumors. We offer innovative, leading-edge therapies and clinical trials not always available elsewhere. Our world-class team of specialists can walk you through the process, address your concerns and create a personalized treatment plan designed to give you the best possible results.
City of Hope is currently enrolling patients with newly developed or recurrent brain tumors for clinical trials. If you are interested in learning our clinical trials or in referring a patient for enrollment, please call 626-471-9393 or email at [email protected].
Why Choose City of Hope
At City of Hope, we treat the whole person, body and soul. We have an unmatched reputation for coordinated, comprehensive and compassionate care. Our brain tumor team has pioneered state-of-the-art procedures that eradicate tumor cells while minimizing side effects. We bring together a broad array of expertise from multiple disciplines, all under one roof:
Plus, your care continues long after treatment, with our unique family and survivorship programs.
Top Ranked Cancer Center
City of Hope is nationally recognized as a leader in the research and treatment of brain tumors. We are designated a Comprehensive Cancer Center by the National Cancer Institute, and U.S. News & World Report has named City of Hope one of the top cancer hospitals in America.
If you have been diagnosed with a brain tumor or are looking for a second opinion consultation about your treatment, request an appointment online or contact us at 800-826-HOPE. Please visit Making Your First Appointment for more information.
City of Hope’s renowned physicians and researchers utilize the latest in technology and innovation to treat adult and pediatric brain cancer, coupled with our enduring belief in providing unparalleled compassionate care.
Like many breast cancer survivors, Joan didn’t know that breast cancer is prone to spread, or metastasize, to the brain. When her cancer returned in the form of a brain tumor, Joan came to City of Hope.
Every patient is different, with different needs. At City of Hope, we design a brain tumor treatment plan just for you. We support you every step of the way, both during treatment and after, helping you and your loved ones manage your recovery.
Learn more about treatment options for brain tumors, including
These procedures include:
Our neurosurgeons also work closely with radiation and medical oncologists so that multiple treatments can be performed in one procedure. For example, after resection they can apply chemotherapy directly to the surgery site, which can kill remaining tumor cells and reduce the likelihood of recurrence.
City of Hope is at the forefront of brain tumor research. We are constantly developing new therapies to eradicate your cancer and minimize side effects. We conduct a wide variety of clinical trials, many of them not available to the general public. Our latest research covers many areas, including: gene therapy and neural stem cell therapy to more effectively deliver cancer-fighting drugs directly to tumors; immunotherapy agents applied through miniature nanotubes; microdialysis catheters to circumvent the “blood-brain barrier.”
City of Hope is currently enrolling patients with newly developed or recurrent brain tumors for clinical trials. If you are interested in learning our clinical trials or in referring a patient for enrollment, please call 626-471-9393 or email at [email protected]. For a summary of this study including the full eligibility criteria, visit City of Hope’s clinical trials website at http://clinicaltrials.coh.org
City of Hope currently has many clinical trials in progress, a number of which address malignant brain tumors. Clinical trials offer patients new and promising experimental treatments not available elsewhere. In fact, nearly one in two patients at City of Hope is part of a clinical trial. These trials evaluate the safety and efficacy of prospective therapies. Participants in clinical trials receive excellent care and are closely monitored. We encourage all brain tumor patients to participate in clinical trials since that will enable us to find better treatments for brain tumors.
For more information about the brain tumor studies listed below including eligibility criteria, please call: 626-471-9393. For a summary of these studies including eligibility criteria, visit the City of Hope clinical trials website.
New Clinical Studies for Recurrent Glioblastoma
IRB #13384: Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma
In this ‘first in human’ clinical study, we are evaluating the safety and feasibility of reprogramming a patient’s own immune system to target malignant glioma. For this study, white blood cells known as T cells are isolated and engineered to express a protein of novel design called a chimeric antigen receptor (CAR). This CAR instructs the T cells to recognize and kill target cells that express IL13Rα2, a receptor readily detected on the majority of malignant gliomas, but not on normal brain tissue.
Research participants will be enrolled on one of two treatment arms based on surgical need: 1) tumor resection or 2) tumor biopsy for non-resectable tumors. At the time of surgery, a catheter system will be placed for local delivery of the reprogrammed T cells at the tumor site. Following recovery from surgery and cell manufacture, research participants will receive weekly injections of the CAR T cells for 3-weeks, with an option for an additional 3-week treatment course.
Patient Eligibility Requirements:
If you are interested in learning more about this clinical trial or in referring a patient for enrollment, please call 626-471-9393 or email [email protected]. For a summary of this study including the full eligibility criteria, visit City of Hope’s clinical trials website at http://clinicaltrials.coh.org and enter “13384” in the keyword search.
IRB# 13401: A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells with Oral 5-Fluorocytosine and Leucovorin for Treatment of Recurrent High-Grade Gliomas
Neural Stem Cells (NSCs) have a natural ability to home to tumor cells throughout the brain. They can be genetically-modified to produce chemotherapy at sites of tumor. Neural stem cells are being investigated as a possible treatment for brain tumors.
During removal or biopsy of tumor, research participants will receive local injections of genetically-modified NSCs. These NSCs express the activating enzyme cytosine deaminase (CD), which converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapy agent 5-fluorouracil (5-FU). Research participants will then take 5-FC orally for seven days. As the 5-FC crosses into the brain, the CD-expressing NSCs (which have migrated to residual cancer sites) are expected to convert the 5-FC into 5-FU. The 5-FU and its toxic metabolites will diffuse out of the NSC to preferentially kill rapidly dividing tumor cells. It is hoped that this strategy will have a large “bystander effect,” meaning that one NSC can kill off many surrounding tumor cells while minimizing toxicity to healthy tissues. Some study patients will also take leucovorin with 5-FC. Leucovorin is an oral medication that can help 5-FU work better against cancer cells. A Rickham catheter, placed in the brain at the time of surgery, will be used to administer additional doses of NSCs every 2 weeks, followed each time by 7 day courses of oral 5-FC (and possibly leucovorin).
Partial Eligibility Requirements:
If you are interested in learning more about this clinical trial or in referring a patient for enrollment, please call 626-471-9393 or email at [email protected]. For a summary of this study including the full eligibility criteria, visit City of Hope’s clinical trials website at http://clinicaltrials.coh.org and enter “13401” in the keyword search.
Additional clinical studies include:
IRB #11180: A Phase III Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma
IRB #13116: A Phase I Gene Therapy Trial of the Safety and Tolerability of Toca 511 in patients Recurrent High Grade Glioma
TOCA 511 & TOCA FC mechanism
This is a very exciting new experimental gene therapy treatment for high grade brain tumors. The basic concept is that a virus (Toca 511) is injected into the tumor. This virus was designed to infect only the brain tumor cells and leave the normal cells alone. When it infects a cell, it adds a gene to the cell which encodes for an enzyme that can convert an antibiotic drug (Toca FC) into a toxic chemotherapy (5-FU), selectively in the tumor. This drug (Toca FC) is given orally every few weeks, and it kills the tumor cells that have enough copies of this enzyme to convert Toca FC to 5-FU. The tumor cells that are infected but don't have enough of the enzyme act as a reservoir - they start the process over again - spreading the infection for a few more weeks, and these cycles are repeated over and over again until the entire tumor is potentially gone.
If you were diagnosed with Recurrent High Grade Glioma (HGG) (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma) that have increased in size following treatment with surgery, radiation therapy and temozolomide. The Toca 511 and Toca FC studies might be the studies for you.
Who can participate in the Toca 511 & Toca FC studies? You may qualify for a Toca 511 & Toca FC study if you:
• Are at least 18 years old (upper limit of 80 years in one of the studies)
• Have recurrent HGG
Your doctor will be able to review with you these and other eligibility criteria. For more information about the Toca 511 & Toca FC studies, please contact Jana Portnow M.D. or Behnam Badie M.D. at 626-471-9393 or visit www.tocagen.com.
IRB #11320: Feasibility of Intraoperative Optical Imaging and Spectroscopy in Brain Tumors
IRB #13459: Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients with Newly Diagnosed or Recurrent Glioblastoma Multiforme. (CELLECTAR)
Learn more about additional brain tumor clinical trials.
When you come to City of Hope, you automatically gain access to an unparalleled array of support services to help you and your family take each step during and after your brain tumor treatment. We can help with all of these concerns, and more:
We deliver exquisite care at the leading edge of cancer treatment. It takes the help of a lot of caring people to make hope a reality for our patients. City of Hope was founded by individuals' philanthropic efforts over 100 years ago. Their efforts - and those of our supporters today - have built the foundation for the care we provide and the research we conduct. It enables City of Hope to strive for new breakthroughs and better therapies - helping more people enjoy longer, better lives.
Watch and read City of Hope brain tumor experts on prevention, screening, treatment and research topics on our Breakthroughs Blog.